Login
$GALT
$3.38 +$0.19 (5.96%) Close

Company Executives

$GALT Management Team

Dr. Khurram Jamil

Chief Medical Officer

Age 49
Compensation $945.8K USD
Sex Male

Mr. Richard Uihlein

Independent Chairman of the Board

Age 79
Compensation $98.00K USD
Sex Male

Mr. Joel Lewis

President

Chief Executive Officer

Director

Age 55
Compensation $1.190M USD
Sex Male

Mr. Jack Callicutt

Chief Financial Officer

Age 58
Compensation $716.9K USD
Sex Male
Directors
11
serving now
Independent
0 of 1
stated in the proxy; 10 not stated
Average tenure
8.4 years
from year joined
CEO also chairs the board
No
Richard E. Uihlein
Director Age On board Independent Committees Other public boards 2025 pay Source
Gilbert F. Amelio, Ph.D.
83 2009
17 years
Not stated
Compensation Committee
None stated $107,760
Henry Brem, M.D.
73 2026
0 years
Not stated None stated None stated Not stated
Benjamin S. Carson, Sr., M.D.
75 2023
3 years
Not stated
Nominating and Corporate Governance Committee
D.R. Horton, Inc. $92,260
Kary Eldred
52 2018
8 years
Not stated None stated None stated $99,760
Kevin D. Freeman
65 2011
15 years
Not stated
Compensation Committee
None stated $108,260
Joel Lewis
56 2017
9 years
Not independent None stated None stated Paid as CEO
Gilbert S. Omenn, M.D., Ph.D.
85 2014
12 years
Not stated None stated None stated $102,260
Elissa J. Schwartz, Ph.D.
56 2020
6 years
Not stated
Nominating and Corporate Governance Committee
None stated $95,760
Harold H. Shlevin, Ph.D.
77 2019
7 years
Not stated None stated None stated $92,260
Richard E. Uihlein
81 2017
9 years
Not stated None stated None stated $92,260
Richard A. Zordani
54 2020
6 years
Not stated None stated None stated $107,260

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Oct 13, 2026
Up to $5.0 million
2025

March 2025 supplemental line of credit letter agreement providing up to $5.0 million, with convertible promissory notes and warrants; the full amount was drawn June 30, 2025.

With the Company Open in proxy
Up to $10.0 million
2025

July 2025 supplemental line of credit letter agreement providing up to $10.0 million, with convertible promissory notes and warrants; the full amount was drawn December 31, 2025.

With the Company Open in proxy
Up to $10.0 million
2025

December 2025 supplemental line of credit letter agreement providing up to $10.0 million, with convertible promissory notes and warrants; undrawn as of June 30, 2026.

With the Company Open in proxy
$91.0 million in aggregate principal and approximately $14.8 million in aggregate accrued interest
2026

Conversion of all outstanding convertible promissory notes from prior credit facilities into 34,376,167 shares of common stock.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support